Parkinson’s Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects

2019-05-31
Price :
Published : May-2019
No. of Pages : 84

Parkinson’s Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects

Summary

Parkinson’s disease (PD), a progressive neurological disorder that affects movement control, is associated with considerable quality of life impairments and burden of care, particularly in the advanced disease stages. Cognitive and behavioral complications of PD are common. PD-associated dementia and PD-associated psychosis are both highly prevalent and associated with a large disease burden.
There is a pressing unmet need within PD, PD-associated dementia, and PD-associated psychosis for more effective disease-modifying pharmacotherapies. Although current therapies can provide patients with symptomatic relief, there are no commercially available agents capable of preventing or slowing the course of PD or its behavioral complications. This report assesses innovation within the pipeline for PD and its behavioral complications.

Scope

– The PD pipeline is large, with 456 programs in active development. Far fewer products are in development for the behavioral complications of PD. There are 16 products in development for PD-associated dementia and six products in development for PD-associated psychosis. What proportion of these products across PD and PD behavioral complications are first in class? How does first-in-class innovation vary by development stage and molecular target class?
– Innovative molecular target groups identified in the pipeline include immunomodulators, neuroprotectants, and protein misfolding and aggregation. Which molecular target classes are prominently represented in the overall and first-in-class pipelines for PD and PD behavioral complications?
– There are 351 companies active across PD and PD behavioral complications. Which companies have the most first-in-class assets in development? Which companies are highly active in terms of licensing and co-development deals for first-in-class innovation?

Reasons to buy

-Understand the current disease landscape with an in-depth discussion of etiology, pathophysiology, disease classification and staging systems, epidemiology, and marketed therapies for PD. Overviews of PD-associated dementia and PD-associated psychosis are also provided.
– Analyze the pipelines for PD, PD-associated dementia, and PD-associated psychosis, and stratify them by stage of development, molecule type, and molecular target.
– Assess the therapeutic potential of first-in-class molecular targets. Using proprietary matrix assessments, first-in-class molecular targets for PD and PD-associated dementia have been assessed and ranked according to clinical potential. A matrix assessment is not provided for PD-associated psychosis due to a lack of first-in-class innovation. Promising first-in-class targets for PD and PD-associated dementia have been reviewed in greater detail.
– Analyze company strategies in prior deals through case studies of key deals for PD first-in-class products, and recognize commercial opportunities by identifying first-in-class pipeline products that have not yet been involved in licensing or co-development deals.

Filed in: Pharmaceutical, Therapeutics
Publisher : GlobalData
More Reports
Title Price Buy Now

Spinal Muscular Atrophy: Epidemiology Forecast in Asia-Pacific Markets to 2028

Spinal Muscular Atrophy: Epidemiology Forecast in Asia-Pacific Markets to 2028 Summary Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease characterized by degeneration of alpha motor neurons in the spinal cord, resulting in progressive proximal muscle weakness and paralysis. The most common form of SMA is 5q SMA, linked to chromosome 5q and its phenotype is classified into four grades of severity (type I, type II, type III, and type IV) based on age of onset and motor function achieved (Amico et al., 2011). Additionally, SMA type 0 is an uncommon form of very severe SMA with prenatal onset (Finkel et al., 2015). In rare cases SMA is also caused by the mutation in another gene and known as non-5q SMA (Verhaart, Robertson, Wilson, et al., 2017). GlobalData epide......
$3495

Wearable Technology in Healthcare – Thematic Research

Wearable Technology in Healthcare - Thematic Research Summary Wearables have the potential to transform healthcare through the ability to remotely measure and analyse patient data in real-time. In addition to health and wellness, they have their greatest potential in healthcare to address spiralling healthcare costs, aging populations, and the burden of chronic disease across the globe. The integration of wearable tech with augmented reality (AR), Big Data, artificial intelligence (AI), and cloud computing solutions, as well as the falling prices of sensors, open-source application programming interfaces (APIs), frameworks, and libraries, is enabling faster and more cost-effective solutions within the Internet of Things (IoT) ecosystem. This report provides an assessment of the key techn......
$1950

Prostate Cancer: Epidemiology Forecast to 2028

Prostate Cancer: Epidemiology Forecast to 2028 Summary Prostate cancer is a malignancy in the prostate gland, which is located below the bladder and in front of the rectum in males. Worldwide, about 1.2 million men were diagnosed with prostate cancer in 2018 (International Agency for Research on Cancer, 2019). Almost all prostate cancers are adenocarcinomas, a type of cancer that develops in gland cells. Most prostate cancers are asymptomatic and grow very slowly. In advanced stages of prostate cancer, the malignancy has spread to other organs such as seminal vesicles, lymph nodes, or bones. When a tumor fails to respond to androgen deprivation therapy, it is referred to as castration-resistant prostate cancer (CRPC) (National Cancer Institute, 2019a). Changes in PSA testing and screenin......
$3995

PharmSource – Contract Small Molecule API Manufacturing Industry by the Numbers – 2019 Edition

PharmSource - Contract Small Molecule API Manufacturing Industry by the Numbers - 2019 Edition Summary This report characterizes the contract small molecule active pharmaceutical ingredient (API) manufacturing industry through a number of quantitative dimensions, including number and type of participants, containment and controlled substance capabilities, and financial performance of the top public contract manufacturing organizations (CMOs). Contract Small Molecule API Manufacturing is critical for establishing an understanding of the small molecule API CMO industry and the features of some of the largest CMOs participating in the industry. Scope Who should buy this report? - This 44-page report gives important, expert insight you won't find in any other source. 26 tables and figures ......
$4995

Respiratory Syncytial Virus: Epidemiology Forecast to 2028

Respiratory Syncytial Virus: Epidemiology Forecast to 2028 Summary Respiratory syncytial virus (RSV) is a common respiratory infection that most children will be infected with by the time they are two years old. In healthy individuals RSV usually self-resolves within a week or two without need for significant therapeutic intervention. In preterm and very young infants, the elderly, or those with otherwise compromised immune systems, however, RSV can cause severe illness or death. It has been estimated that up to 30 million episodes of RSV-related lower respiratory infection occur annually worldwide, with the majority of those cases occurring in low-income countries. RSV is also considered to be the leading cause of bronchiolitis and pneumonia in children less than one year old and one o......
$3995

Ovarian Cancer: Epidemiology Forecast to 2028

Ovarian Cancer: Epidemiology Forecast to 2028 Summary Ovarian cancer is the most lethal gynecologic cancer and overall a leading cause of cancer incidence and mortality worldwide. The disease is defined as uncontrolled cell growth in the ovaries, although research has shown that the disease may actually originate in the fallopian tubes. GlobalData epidemiologists used age- and sex-specific diagnosed incidence rates to forecast the diagnosed incident cases, and used the observed survival rates to calculate the five-year diagnosed prevalent cases, taking into account the significant relationship between age and ovarian cancer incidence, survival, and prevalence. GlobalData epidemiologists applied country-specific incidence rates of ovarian cancer, wherever available, to each country's pop......
$3995

Alopecia Areata: Epidemiology Forecast to 2028

Alopecia Areata: Epidemiology Forecast to 2028 Summary Alopecia areata (AA) is a common, clinically heterogeneous, immune-mediated and a non-scarring hair loss disorder (Hordinsky, 2013). It typically presents with sharply demarcated round patches of hair loss and may present at any age. Experimental and clinical evidence suggests that AA is caused by autoimmune attack against the hair follicles. The precise path mechanism, however, remains unknown (Dainichi and Kabashima, 2017). GlobalData epidemiologists utilized national databases and robust peer-reviewed journal articles to build the forecast for the diagnosed incident and prevalent cases of AA in the 7MM. GlobalData epidemiologists applied country-specific incidence and prevalence rates of AA, wherever available, to each country's......
$3995

Partnerships, Licensing, Investments and M&A Deals and Trends for May 2019 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for May 2019 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for May 2019 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in May 2019. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides inform......
$1000

Partnerships, Licensing, Investments and M&A Deals and Trends for June 2019 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for June 2019 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for June 2019 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in June 2019. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides inf......
$1000

Spinal Muscular Atrophy (SMA) : Opportunity Analysis and Forecasts to 2028

Spinal Muscular Atrophy (SMA): Opportunity Analysis and Forecasts to 2028 Summary SMA is an area that is expected to witness strong growth in the future, primarily due to launch of pipeline products that are expected to gradually capture market share from Biogen's Spinraza. Also, the launch of survival motor neuron (SMN)- independent therapies are expected to be used in conjunction with an SMN-dependent therapy and this is also expected to contribute to SMA market growth in the forecast period. Established pharmaceutical companies as well as smaller biotechnology companies are leading the development of pipeline products. Developmental challenges include the need for long-term safety and clinical data for SMA drugs especially those that are proposed to work by gene-therapy, the need ......
$10995
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy